POSTDOCTORAL RESEARCH SCIENTIST
I studied undergraduate Biochemistry at the University of Birmingham during which, I completed a year in Industry at Astra Zeneca studying drug induced mitochondrial toxicity. Following this I joined the Wellcome Trust Centre for Mitochondrial Research, Newcastle University and conducted an MRes, characterising mitochondrial physiology in patient derived induced pluripotent stem cells (iPSCs) and a PhD developing assays to identify compounds for the treatment of mitochondrial disease in collaboration with Novartis. Following this, I conducted pre-clinical assessment of compounds for Reneo Pharmaceuticals to determine the effect of lead therapies on mitochondrial function in Complex I deficient iPSC derived myotubes.
I joined the Wade-Martins group in 2018 and will be conducting novel target identification and validation for the treatment of Parkinson’s disease alongside the pharmaceutical company FORMA therapeutics.